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This form of resistance has been detected in Peru since 1996.
We have an excellent DOT with very good outcomes, how-
ever, the paradox of having a sensible TB and a growth of
MDR TB is no easy to explain.
We could try to explain the reasons due to a low preva-
lence of Beijing strain (<10%) and administrative delay in
starting speciﬁc treatment of 12—15 months detected in the
period of 1995 to 2003. This administrative delay happened
because after a treatment failure to ﬁrst and second line
therapy, an overall of 12 months; at this moment, cultures
and diagnosis for INH/Rifampin resistance were taken. The
results took about 3 months, and it was then when we could
start a speciﬁc treatment.
During all this time, is estimated that a TB patient
could infect between 2 to 25 people. This situation could
be the cause of infection in the homes, health centers
care, patients in the ER with predisposition like AIDS/HIV
and Diabetes, and Health Care Personnel that took care of
this patients without an adequate protection. Newcomer’s
molecular studies could help to ﬁnd the answers to this spe-
cial situation.
doi:10.1016/j.ijid.2008.05.129
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Japanese encephalitis (JE) is a signiﬁcant but solvable pub-
lic health problem. Safe, effective, and affordable vaccines
are available to prevent this devastating disease. However,
the introduction or expansion of JE immunization programs
is often delayed because disease burden is unknown or
underestimated. In several countries where JE virus trans-
mission has been proven and sporadic cases have been
recognized, JE surveillance does not exist. In other coun-
tries, the quality and accuracy of existing surveillance data
are uncertain. Although WHO has published JE surveillance
standards, these guidelines have yet to be implemented in
most countries. Therefore, the numbers and characteristics
of JE cases cannot be easily compared between countries or
over time. In addition, long-term sequelae associated with
JE are often not measured, resulting in an underestimate of
the full economic and social impact of the disease. Most
JE cases are diagnosed based on clinical syndrome (i.e.,
encephalitis) without laboratory conﬁrmation. This practice
can perpetuate established biases in the epidemiology of JE
because cases are only reported from known endemic areas
during predeﬁned transmission seasons. As a result, JE may
be underreported from areas that lack well-deﬁned seasonal
peaks in encephalitis cases, or among patients with unique
clinical presentations (i.e., acute ﬂaccid paralysis) or demo-
graphics (i.e., adults). In addition, encephalitis cases due
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o other etiologies are erroneously attributed to JE virus
nfection and sometimes misclassiﬁed as vaccine failures
r vaccine-associated adverse events. Although many lab-
ratories perform JE diagnostic testing, several steps are
eeded to ensure the accuracy, reliability, and compara-
ility of the results. Laboratories supporting surveillance
fforts should use validated diagnostic assays and standard-
zed testing protocols with strong quality assurance and
uality control programs. Improved surveillance with accu-
ate laboratory-based diagnostics is an essential step for
etter understanding the epidemiology and true burden of
E, and for directing and evaluating effective immunization
trategies.
oi:10.1016/j.ijid.2008.05.130
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Program for Appropriate Technology in Health, Jakarta,
ndonesia
ackground: A two-year prospective study was conducted
rom January 2005 to December 2006 to estimate the mag-
itude of Japanese encephalitis (JE) disease burden in
ndonesia. All children 15 years of age and under presenting
ith acute encephalitis syndrome (AES) to selected hospital
nd health center sites were identiﬁed and laboratory test-
ng was conducted to conﬁrm the proportion of cases due to
E virus infection. Epidemiological data were collected to
mprove understanding of JE disease in Indonesia.
Methods: Six provinces with different assumed risks for
E virus transmission were included. At ﬁfteen hospital and
ealth center sites, paired sera, cerebrospinal ﬂuid samples,
nd at some sites ﬁlter paper specimens, were taken from
atients whomet theWHO criteria for AES. They were tested
or antibody to JE and dengue viruses using immunoglobulin
antibody capture ELISA at the National Institute of Health
esearch and Development in Jakarta.
Results: 1496 AES patients (1401 from hospitals, 95 from
ealth centers) were recorded. 74.9% (n = 1120) were <5
ears old, and 57.6% (n = 862) were male. 82 patients (5.5%)
ad IgM antibody to JE virus: of these, 70.7 % (n = 58) were
ged <5 years, and 56.1% (n = 46) were males. The average
ength of hospitalization of JE positive patients was sig-
iﬁcantly longer than those who tested JE negative (12.7
ays and 8.8 days, respectively; p = 0.03); they were also
ore likely to suffer from sequelae than those without JE
RR = 3.12; p < 0.001). Having pig rearing nearby (less than
km from the house) was the main risk factor associated
ith acute JE infection (p = 0.004). However, about half of
he JE patients did not live close to a pig population, sug-
esting that other amplifying hosts such as water birds are
lso involved in JE virus transmission in Indonesia.
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the international community can sustain and expand this
momentum to develop a comprehensive control effort in all
disease-endemic countries.
doi:10.1016/j.ijid.2008.05.13334 13th Internat
Conclusion: JE patients were found in all study sites,
nd sequelae were found in a high proportion of patients. A
ational program of JE vaccination is certainly worth con-
ideration.
oi:10.1016/j.ijid.2008.05.131
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he ﬁrst recorded major outbreak of Japanese encephalitis
JE) in Sri Lanka occurred in 1985—86 with 385 cases and 64
eaths in the North Central province. Outbreaks occurred
n 1986—87 and 1987—88, the latter being the largest with
12 cases and 192 deaths in three adjoining districts. Cases
ccurred in rice cultivating areas with a network of irrigation
anals supported by seasonal, moderate to heavy rainfall.
hildren aged 5— and young adults aged 20—24 years were
redominantly affected.
JE was also spreading to new areas with previously
ow transmission. To cope with this emerging challenge,
he Ministry of Health’s Epidemiology Unit initiated phased
E immunization in 1988. Children aged 1—10 years were
ffered three primary doses and a booster of inactivated
accine in the interpandemic period through a campaign
pproach. Over the years, JE incidence decreased as immu-
isation coverage increased. However, cases and occasional
utbreaks were reported in other districts where immuniza-
ion was not carried out, and the programme ultimately
xpanded to 18 districts.An increasing trend of adverse
vents following immunization with the inactivated JE vac-
ine threatened repercussions to the programme. Another
bstacle was the increasing cost of the inactivated vaccine-
S$4.50 per dose in 2006, a prohibitive factor to programme
ustainability. Identifying an affordable, safe and immuno-
enic vaccine alternative was a high priority.
The live, attenuated SA 14-14-2 JE vaccine (LJEV)
ppeared to be an appropriate, low cost, safe and potent
lternative. With support from PATH, the Epidemiology Unit
nitiated a clinical trial in 2007 to ascertain the safety and
mmunogenicity of LJEV. Based on preliminary results, the
overnment decided to introduce LJEV in place of the inacti-
ated vaccine, hopefully expanding to routine EPI very soon.
Currently, the Ministry of Health is negotiating a public
ector price for procurement of LJEV and ﬁnalizing the rec-
mmended schedule. Cost savings from transitioning to LJEV
ill enable the introduction of new vaccines and will extend
he JE immunization programme to adults in high endemic
reas.
oi:10.1016/j.ijid.2008.05.132l Congress on Infectious Diseases Abstracts (Invited Papers)
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JE is the leading cause of viral neurological infection
encephalitis) in the Asian region, primarily affecting chil-
ren aged 1-15 years in rural areas. JE vaccination has
een successful in effectively controlling the disease in
any countries where JE was identiﬁed as a public health
roblem, often linked to epidemic manifestation. These
xperiences show the way to successful JE control and,
ecently, several additional countries have started to intro-
uce JE vaccination.
Today, there is great opportunity to sustain and expand
omentum for JE control through vaccination, building on
ecent advances achieved through country, WHO and part-
ers’ efforts, in particular PATH. Increasingly, countries are
stablishing surveillance to document the burden of disease.
ive, attenuated vaccine has shown great potential in pre-
enting disease and is becoming available in large volume
t a highly preferential public-sector price. Additionally,
romising JE vaccines under development should become
icensed for pediatric use during the coming years. More-
ver, cost-effectiveness analysis gives favorable ﬁgures in
any country settings (estimated 75$/DALY loss averted for
AVI-eligible countries), providing a strong rationale for vac-
ine introduction. Most important, however, is public and
overnment recognition of the JE problem, and the will to
ake action.
To advance sustainable introduction of JE vaccination
here it matters, priorities include documentation of dis-
ase burden -in particular in countries with no visible
pidemics-and the establishment of a public sector report-
ng system. Building local capacity for strengthening JE
urveillance, including quality-assured diagnostic laborato-
ies, is key. The decision on vaccine introduction and optimal
mmunization strategy has to follow a rationale process
s recommended for any other vaccine, with a particular
mphasis on cost-effectiveness analysis and ﬁnancial and
anagerial planning to sustain the effort beyond initial cam-
aigns. This includes an assured vaccine procurement plan
nd an AEFI system to monitor vaccine safety.
Countries have shown leadership in introducing JE vac-
ination. Targeted ﬁnancial and technical support from
